Molecular Analysis Needed to Guide Further Study of Olaparib Plus Ceralasertib in Pediatric Advanced Cancers
The combination of PARP and ATR inhibition with olaparib and ceralasertib was tolerable but showed limited efficacy in pediatric patients with advanced malignancies harboring DNA replication stress and DNA repair deficiencies, according to findings from arm N of the phase 1/2 AcSé-ESMART trial.
United Kingdom Susanne Gatz Genomic Sciences Of The University Birmingham Institute Of Cancer Genomic Sciences Bayesian Optimal
Source: onclive.com